ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

ClinicalTrials.gov ID: NCT04173494

Public ClinicalTrials.gov record NCT04173494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 4:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy

Study identification

NCT ID
NCT04173494
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Enrollment
195 participants

Conditions and interventions

Interventions

  • Danazol Drug
  • Momelotinib Drug
  • Placebo to match danazol Drug
  • Placebo to match momelotinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 6, 2020
Primary completion
Dec 2, 2021
Completion
Dec 28, 2022
Last update posted
Oct 31, 2023

2020 – 2022

United States locations

U.S. sites
17
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
Mayo Clinic Hospital - Phoenix Phoenix Arizona 85054
Irvine Center for Clinical Research Irvine California 92614
Norris Comprehensive Cancer Center Los Angeles California 91011
American Institute of Research - Whittier Whittier California 90603
University of Colorado Hospital Anschutz Cancer Pavilion Aurora Colorado 80045
Georgetown University Medical Center Washington D.C. District of Columbia 20057
Moffitt Cancer Center Tampa Florida 33612
Northwest Oncology & Hematology - Rolling Meadows Rolling Meadows Illinois 60008
Washington University School of Medicine in Saint Louis St Louis Missouri 63110
Hackensack University Medical Center Hackensack New Jersey 07601
Columbia University Irving Medical Center - Presbyterian Hospital New York New York 10032
Cleveland Clinic - Richard E. Jacobs Health Center Avon Ohio 44011
Gabrail Cancer Center Canton Ohio 44718
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Allegheny Health Network Pittsburgh Pennsylvania 15224
The University of Texas MD Anderson Cancer Center Houston Texas 77030
The University of Texas Health Science Center at San Antonio San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 150 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04173494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 31, 2023 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04173494 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →